Literature DB >> 2803924

The effect of serum CEA on the distribution and clearance of anti-CEA antibody in a pancreatic tumour xenograft model.

R B Pedley1, J A Boden, R W Boden, A Green, G M Boxer, K D Bagshawe.   

Abstract

A human pancreatic adenocarcinoma was used to develop two histologically distinct xenograft lines, one associated with high levels (180-2000 ng ml-1) and one with low levels (greater than 2.0 less than 8.0 ng ml-1) of serum carcinoembryonic antigen (CEA). A strong correlation was found between tumour size and both circulating and tumour CEA levels in the former group, and also correlation at the 5% level between tumour size and serum CEA in the latter. Administration of either monoclonal or polyclonal 125I-anti-CEA antibody led to the formation of intravascular antigen-antibody immune complexes in mice with high CEA levels, and these were rapidly cleared by the liver, deiodination commencing within the first hour. Blood activity was reduced to 20% of the injected dose by 15 min, and by 24 h the radioactivity in all tissues except muscle was significantly below that found in either the low CEA group or in mice without tumours. No difference in radio-antibody clearance pattern was found between mice without tumours and the group with low levels of serum CEA. In spite of higher levels of CEA within the tumour in mice with elevated serum CEA, the rapid clearance of antigen-antibody complexes reduced tumour localisation to one quarter of that seen in mice with low serum, and correspondingly low tumour, CEA levels. Gamma-camera imaging confirmed these results. Possible implications to patient selection and treatment are discussed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2803924      PMCID: PMC2247110          DOI: 10.1038/bjc.1989.311

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  18 in total

1.  Photoscan localization of GW-39 tumors in hamsters using radiolabeled anticarcinoembryonic antigen immunoglobulin G.

Authors:  D M Goldenberg; D F Preston; F J Primus; H J Hansen
Journal:  Cancer Res       Date:  1974-01       Impact factor: 12.701

2.  Metabolism of human carcinoembryonic antigen in xenogeneic animals.

Authors:  J Shuster; M Silverman; P Gold
Journal:  Cancer Res       Date:  1973-01       Impact factor: 12.701

3.  Carbohydrate-mediated clearance of immune complexes from the circulation. A role for galactose residues in the hepatic uptake of IgG-antigen complexes.

Authors:  R W Thornburg; J F Day; J W Baynes; S R Thorpe
Journal:  J Biol Chem       Date:  1980-07-25       Impact factor: 5.157

4.  Radioimmunodetection of cancer with radioactive antibodies to carcinoembryonic antigen.

Authors:  D M Goldenberg; E E Kim; F H DeLand; S Bennett; F J Primus
Journal:  Cancer Res       Date:  1980-08       Impact factor: 12.701

5.  Prognostic factors in colon carcinoma: correlation of serum carcinoembryonic antigen level and tumor histopathology.

Authors:  N Zamcheck; W G Doos; R Prudente; B B Lurie; L S Gottlieb
Journal:  Hum Pathol       Date:  1975-01       Impact factor: 3.466

6.  Antibody to carcinoembryonic antigen in hamsters bearing GW-39 human tumors.

Authors:  F J Primus; R H Wang; E Cohen; H J Hansen; D M Goldenberg
Journal:  Cancer Res       Date:  1976-07       Impact factor: 12.701

7.  Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning.

Authors:  D M Goldenberg; F DeLand; E Kim; S Bennett; F J Primus; J R van Nagell; N Estes; P DeSimone; P Rayburn
Journal:  N Engl J Med       Date:  1978-06-22       Impact factor: 91.245

8.  Clearance of injected radioactively labelled antibodies to tumour products by liposome-bound second antibodies.

Authors:  P A Keep; F Searle; R H Begent; G M Barratt; J Boden; K D Bagshawe; B E Ryman
Journal:  Oncodev Biol Med       Date:  1983

9.  Circulating immune complexes in cancer patients receiving goat radiolocalizing antibodies to carcinoembryonic antigen.

Authors:  F J Primus; S J Bennett; E E Kim; F H DeLand; M C Zahn; D M Goldenberg
Journal:  Cancer Res       Date:  1980-03       Impact factor: 12.701

10.  DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES.

Authors:  P GOLD; S O FREEDMAN
Journal:  J Exp Med       Date:  1965-03-01       Impact factor: 14.307

View more
  4 in total

Review 1.  Monoclonal antibody administration. Current clinical pharmacokinetic status and future trends.

Authors:  R H Begent; R B Pedley; J Begent
Journal:  Clin Pharmacokinet       Date:  1992-08       Impact factor: 6.447

2.  Preliminary observations on the microdistribution of labelled antibodies in human colonic adenocarcinoma xenografts: relevance to microdosimetry.

Authors:  R B Pedley; G M Boxer; J A Boden; P J Southall; R H Begent; K D Bagshawe; J Humm; F Searle
Journal:  Br J Cancer       Date:  1990-02       Impact factor: 7.640

3.  Factors influencing variability of localisation of antibodies to carcinoembryonic antigen (CEA) in patients with colorectal carcinoma--implications for radioimmunotherapy.

Authors:  G M Boxer; R H Begent; A M Kelly; P J Southall; S B Blair; N A Theodorou; P M Dawson; J A Ledermann
Journal:  Br J Cancer       Date:  1992-06       Impact factor: 7.640

4.  Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments.

Authors:  J L Casey; R B Pedley; D J King; A J Green; G T Yarranton; R H Begent
Journal:  Br J Cancer       Date:  1999-11       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.